The choice of the medicine phosphodiesterase inhibitors of 5th type for treating patients with erectile dysfunction and chronic prostatitis
The study of the genital system' vessels in patients with erectile disfunction and chronic prostatitis was accomplished using ultrasound Dopplerography and pharmacological testing by phosphodiesterase inhibitors of 5th type (PDEI-5). The positive impact of PDEI-5 (such as Sildenafil, Vardenafil...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
2013-06-01
|
| Series: | Сеченовский вестник |
| Subjects: | |
| Online Access: | https://www.sechenovmedj.com/jour/article/view/781 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839588815379890176 |
|---|---|
| author | P. V. Glybochko Yu. G. Alyaev Yu. M. Esilevskiy A. A. Kamalov Yu. L. Demidko D. N. Fiev |
| author_facet | P. V. Glybochko Yu. G. Alyaev Yu. M. Esilevskiy A. A. Kamalov Yu. L. Demidko D. N. Fiev |
| author_sort | P. V. Glybochko |
| collection | DOAJ |
| description | The study of the genital system' vessels in patients with erectile disfunction and chronic prostatitis was accomplished using ultrasound Dopplerography and pharmacological testing by phosphodiesterase inhibitors of 5th type (PDEI-5). The positive impact of PDEI-5 (such as Sildenafil, Vardenafil, Udenafil and Tadalafil) on organs' blood supply was revealed. The changes of USDG parameters were found comparable and, at the same time, individual. For patient-specific choosing the medicinal agent it is advisable to perform the pharmacological tests for each patient. The choice of the medicine for treating erectile disfunction and chronic prostatitis should be made on the basis of the results of ultrasound Dopplerography and pharmacological testing for each selected and tested medicine. For this purpose it is preferably to choose the medicine, which improves the blood flow in penis and, at the same time, in prostate gland and in testes. |
| format | Article |
| id | doaj-art-c37c4fea0bb54dddba926d26f20b0cf5 |
| institution | Matheson Library |
| issn | 2218-7332 2658-3348 |
| language | Russian |
| publishDate | 2013-06-01 |
| publisher | Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) |
| record_format | Article |
| series | Сеченовский вестник |
| spelling | doaj-art-c37c4fea0bb54dddba926d26f20b0cf52025-08-03T13:30:21ZrusFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Сеченовский вестник2218-73322658-33482013-06-01023340475The choice of the medicine phosphodiesterase inhibitors of 5th type for treating patients with erectile dysfunction and chronic prostatitisP. V. Glybochko0Yu. G. Alyaev1Yu. M. Esilevskiy2A. A. Kamalov3Yu. L. Demidko4D. N. Fiev5The I.M. Sechenov First MSMUThe I.M. Sechenov First MSMUThe I.M. Sechenov First MSMUThe M.V. Lomonosov MSUThe I.M. Sechenov First MSMUThe I.M. Sechenov First MSMUThe study of the genital system' vessels in patients with erectile disfunction and chronic prostatitis was accomplished using ultrasound Dopplerography and pharmacological testing by phosphodiesterase inhibitors of 5th type (PDEI-5). The positive impact of PDEI-5 (such as Sildenafil, Vardenafil, Udenafil and Tadalafil) on organs' blood supply was revealed. The changes of USDG parameters were found comparable and, at the same time, individual. For patient-specific choosing the medicinal agent it is advisable to perform the pharmacological tests for each patient. The choice of the medicine for treating erectile disfunction and chronic prostatitis should be made on the basis of the results of ultrasound Dopplerography and pharmacological testing for each selected and tested medicine. For this purpose it is preferably to choose the medicine, which improves the blood flow in penis and, at the same time, in prostate gland and in testes.https://www.sechenovmedj.com/jour/article/view/781ultrasound dopplerographypharmacological testingpenisprostate glandtestessildenafilvardenafiludenafiltadalafilerectile disfunctionchronic prostatitisphosphodiesterase inhibitor selection |
| spellingShingle | P. V. Glybochko Yu. G. Alyaev Yu. M. Esilevskiy A. A. Kamalov Yu. L. Demidko D. N. Fiev The choice of the medicine phosphodiesterase inhibitors of 5th type for treating patients with erectile dysfunction and chronic prostatitis Сеченовский вестник ultrasound dopplerography pharmacological testing penis prostate gland testes sildenafil vardenafil udenafil tadalafil erectile disfunction chronic prostatitis phosphodiesterase inhibitor selection |
| title | The choice of the medicine phosphodiesterase inhibitors of 5th type for treating patients with erectile dysfunction and chronic prostatitis |
| title_full | The choice of the medicine phosphodiesterase inhibitors of 5th type for treating patients with erectile dysfunction and chronic prostatitis |
| title_fullStr | The choice of the medicine phosphodiesterase inhibitors of 5th type for treating patients with erectile dysfunction and chronic prostatitis |
| title_full_unstemmed | The choice of the medicine phosphodiesterase inhibitors of 5th type for treating patients with erectile dysfunction and chronic prostatitis |
| title_short | The choice of the medicine phosphodiesterase inhibitors of 5th type for treating patients with erectile dysfunction and chronic prostatitis |
| title_sort | choice of the medicine phosphodiesterase inhibitors of 5th type for treating patients with erectile dysfunction and chronic prostatitis |
| topic | ultrasound dopplerography pharmacological testing penis prostate gland testes sildenafil vardenafil udenafil tadalafil erectile disfunction chronic prostatitis phosphodiesterase inhibitor selection |
| url | https://www.sechenovmedj.com/jour/article/view/781 |
| work_keys_str_mv | AT pvglybochko thechoiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT yugalyaev thechoiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT yumesilevskiy thechoiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT aakamalov thechoiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT yuldemidko thechoiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT dnfiev thechoiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT pvglybochko choiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT yugalyaev choiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT yumesilevskiy choiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT aakamalov choiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT yuldemidko choiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis AT dnfiev choiceofthemedicinephosphodiesteraseinhibitorsof5thtypefortreatingpatientswitherectiledysfunctionandchronicprostatitis |